Passive immunization against tumor necrosis factor partially abrogates interleukin 2 toxicity.
about
Forecasting the cytokine storm following systemic interleukin (IL)-2 administrationGene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administrationPentoxifylline inhibits interleukin-2-induced toxicity in C57BL/6 mice but preserves antitumor efficacy.Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cellsA CAT reporter construct allows ultrasensitive estimation of TNF synthesis, and suggests that the TNF gene has been silenced in non-macrophage cell lines.The tetravalent guanylhydrazone CNI-1493 blocks the toxic effects of interleukin-2 without diminishing antitumor efficacyMolecular signatures induced by interleukin-2 on peripheral blood mononuclear cells and T cell subsetsEvidence for cytokine-inducible nitric oxide synthesis from L-arginine in patients receiving interleukin-2 therapyTherapeutic potential for cytokine antagonists: Thalidomide and pentoxifylline in Hansen's disease.Temporal sequence and cellular origin of interleukin-2 stimulated cytokine gene expressionFlavone acetic acid (FAA) with recombinant interleukin-2 (rIL-2) in advanced malignant melanoma. III: Cytokine studies.The activation of polymorphonuclear neutrophils and the complement system during immunotherapy with recombinant interleukin-2.Interleukin 2-induced increase of vascular permeability without decrease of the intravascular albumin pool.Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes.A recombinant human receptor antagonist to interleukin 1 improves survival after lethal endotoxemia in miceInteractions between rnacrophage cytokines and eicosanoids in expression of antitumour activityPotential use of IL-2/anti-IL-2 antibody immune complexes for the treatment of cancer and autoimmune disease.The role of cytokines, adhesion molecules, and chemokines in interleukin-2-induced lymphocytic infiltration in C57BL/6 mice.The immunotherapy of human cancer with interleukin 2: present status and future directions.Interleukin-12: a recently discovered cytokine with potential for enhancing cell-mediated immune responses to tumors.Interleukin 2 induces tumor necrosis factor gene expression in vivo.Systemic administration of interleukin-2 inhibits inflammatory neutrophil migration: role of nitric oxide.
P2860
Q24796741-CA8310E4-C245-4128-9305-F8C8D77BC588Q24802736-AB1EADF0-68D4-42E2-BB0B-A98E14B01F5FQ33370145-ADCFB568-5464-4573-AB2F-7D9B843F9C99Q33977597-4A24827C-FDF7-474C-B5EE-0A8792BB0330Q34183889-07AFE5A0-A609-4F13-9CD9-41ED41FB68A8Q34463802-CE94AC7B-CE95-401E-9F70-F68B936E87CBQ35012607-AD083F6F-0697-4938-A745-6B1C19A72994Q35599161-8C71CAB7-9AD4-4BB8-9577-B2F81F9F3049Q35892890-523B6645-92A9-45FB-9725-B2400898A80EQ35976007-25D7C864-6FCB-43A4-A694-776ECB135646Q35977092-3C5EB2FB-AA8F-470A-85C3-423F6DE424F8Q35992936-5741C8E0-DAFC-45ED-8EEF-4D7F666CF4AAQ36079858-B473D6F1-AE29-485A-972F-DAE4DBAFFACCQ36230021-77B61FDA-E489-4A79-8235-A40CA9EAA5DAQ36360996-D3B8F9C8-DC9B-46B3-AF0F-47FBDD3BFC93Q36627020-E884D0B1-928C-48C0-A90D-E6169763D04BQ36708311-91CE9844-F428-4AA7-A2C2-4F6A21D61694Q37354383-EE54286F-F7CF-4A64-A252-D668B030B526Q37427683-2181F4B6-852C-46E3-A8E3-EC732A420EDFQ40711010-55467DB8-9BA8-417C-AF2C-641A86A3C905Q41169638-6D71A635-C982-4185-8584-A30D9A3EC130Q43054090-E848328B-054E-4241-80BD-0DD7A767ECCF
P2860
Passive immunization against tumor necrosis factor partially abrogates interleukin 2 toxicity.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
1989年學術文章
@zh
1989年學術文章
@zh-hant
name
Passive immunization against t ...... ogates interleukin 2 toxicity.
@ast
Passive immunization against t ...... ogates interleukin 2 toxicity.
@en
type
label
Passive immunization against t ...... ogates interleukin 2 toxicity.
@ast
Passive immunization against t ...... ogates interleukin 2 toxicity.
@en
prefLabel
Passive immunization against t ...... ogates interleukin 2 toxicity.
@ast
Passive immunization against t ...... ogates interleukin 2 toxicity.
@en
P2093
P2860
P356
P1476
Passive immunization against t ...... ogates interleukin 2 toxicity.
@en
P2093
Langstein HN
P2860
P304
P356
10.1084/JEM.170.3.1015
P407
P577
1989-09-01T00:00:00Z